Dong-A Socio Holdings Co., Ltd. (KRX:000640)

Market Cap	776.15B +28.7%
Revenue (ttm)	1.40T +9.0%
Net Income	107.66B +95.5%
EPS	16,724.68 +95.5%
Shares Out	6.44M
PE Ratio	7.21
Forward PE	7.20
Dividend	1,650.49 (1.38%)
Ex-Dividend Date	n/a

Volume	18,619
Average Volume	18,181
Open	120,100
Previous Close	119,900
Day's Range	118,200 - 121,900
52-Week Range	94,078 - 125,500
Beta	-0.08
RSI	71.58
Earnings Date	Feb 9, 2026

About Dong-A Socio Holdings

Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical tri...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 5,653
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000640

Financial Performance

In 2024, Dong-A Socio Holdings's revenue was 1.33 trillion, an increase of 17.78% compared to the previous year's 1.13 trillion. Earnings were 58.02 billion, an increase of 0.06%.